Milestones
Research and company milestones, from the first publications to today.
Research chronology
2019: Bench and human feasibility reports
2020: Ultrastructure and engineering publications
June 2021: DoD-funded randomized study (NCT04794621) begins at Indiana University
2022: Veterinary case reports published in Veterinary Surgery
July 2023: DoD-funded randomized study (NCT04794621) completed at Indiana University
September 2025: Murine preclinical study published in PLOS One
April 2026: Review article published in Frontiers in Microbiology
Building the company
September 2023: Pavaka Wound Care founded in Columbus, Ohio, by Brent Toto and Frank Fischer
October 2024: U.S. Patent 12,102,508 issued, “Antimicrobial Wound Care Dressing”
January 2025: Exclusive license from The Ohio State University announced
February 2025: Featured by The Ohio State University College of Engineering
April 2025: Ohio Third Frontier TVSF Phase 2 award ($200,000) from the Ohio Department of Development
July 2025: Graduated from Rev1 Concept to Customer, winning first place in the cohort peer vote
August 2025: Preliminary findings from the DoD-funded randomized study presented at MHSRS 2025
August–November 2025: Rev1 Customer to Capital accelerator, Fall 2025 cohort
November 2025: Rev1 Ventures Concept Contract funding ($150,000)
January 2026: Robert J. O’Connell, MD, joined as CMO & Director of Military Affairs
March 2026: Exhibited at OPMED 2026, San Antonio
April 2026: Wound Shark finalist, Wound Healing Society 2026 Annual Meeting at SAWC Spring (Charlotte)
June 2026: Two U.S. provisional patent applications filed on next-generation dressing designs
August 2026: Participated in MHSRS 2026 (Military Health System Research Symposium)
August 2026: USPTO Notice of Allowance for a second U.S. patent application
August 2026: Gen 2 dressing design completed with The Fischer Group under the Ohio TVSF grant; the six-volt Gen 2 configuration performed equivalently to Gen 1 in a laboratory agar assay at the University of Pittsburgh
What’s next
FDA pre-submission meeting for the Gen 2 dressing
510(k) submission for the three-volt Gen 2 configuration
De Novo pathway for the six-volt Gen 2 configuration, seeking a biofilm-related indication
First commercial focus: orthopedic and foot-and-ankle surgery
Plans are forward-looking and depend on FDA feedback and funding.
